Modeling Best Practices of Medically Integrated Pharmacies to Improve Treatment Monitoring and Therapy Adherence in Patients
Tracking # 20-1314912
Free
There are no ratings for this course
Learn moreCourse overview
To receive credit, learners are required to complete the assessment, view the content , and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A statement of participation will be immediately available. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days. There is no fee to participate in the activity or for the generation of the participation statement.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Purdue University College of Pharmacy and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None